Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA) ...Middle East

SAN FRANSCISO and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, cardiovascular and...

Hence then, the article about innovent and sanegenebio announce first participant dosed in a phase 1 clinical trial of ibi3016 agt sirna was published today ( Friday 02/08/2024 - 03:37 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA) )

Also on site :

• Hollywood mourns loss of beloved makeup artist Jasen Kaplan
• My Husband Claimed He Was OK With My Extracurricular Sex Activities. My Biggest Mistake Was Believing Him.
• Suspected mountain lion attack in Colorado mountains under investigation